This is remarkable results for a vaccine therapy. This is the first reported results of a treatment used for brain tumors under the Right To Try law. They treated patients with recurrent Glioblastoma who historically lived an average of 8 months. With this treatment, average survival was 19.6 months, with 25% of patients alive at the end of the trial at about the 40 month mark. They are tweaking the protocol to make it work even better. There was minimal side effects.
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide